POS-829 Incidence and predictors of hyperkalaemia in patients with CKD and T2D in the FIDELIO-DKD trial

• R. Agarwal,
• A. Joseph,
• P. Rossing,
• B. Pitt,
• S. Anker D,
• G. Filippatos,
• L. Ruilope M,
• P. Kolkhof,
• C. Scott,
• R. Lawatscheck,
• G. Bakris L

Affiliations

R. Agarwal

Richard L. Roudebush VA Medical Center and Indiana University, School of Medicine, Indianapolis, United Kingdom

A. Joseph

Bayer AG, Cardiology and Nephrology Clinical Development, Berlin, Germany

P. Rossing

Steno Diabetes Center Copenhagen and University of Copenhagen, Department of Clinical Medicine, Copenhagen, Denmark

B. Pitt

University of Michigan School of Medicine, Department of Medicine, Ann Arbor, United States

S. Anker D

Berlin Institute of Health Center for Regenerative Therapies- German Centre for Cardiovascular Research Partner Site Berlin- Charité Universitätsmedizin, Department of Cardiology CVK, Berlin, Germany

G. Filippatos

National and Kapodistrian University of Athens- School of Medicine- Attikon University Hospital, Department of Cardiology, Athens, Greece

L. Ruilope M

Institute of Research imas12 & CIBER-CV- Hospital Universitario 12 de Octubre and European University of Madrid, Cardiorenal Translational Laboratory and Hypertension Unit & Faculty of Sport Sciences, Madrid, Spain

P. Kolkhof

Bayer AG, Research and Development- Preclinical Research Cardiovascular, Wuppertal, Germany

C. Scott

Bayer PLC, Data science and analytics, Reading, United Kingdom

R. Lawatscheck

Bayer AG, Medical Affairs & Pharmacovigilance- Pharmaceuticals, Berlin, Germany

G. Bakris L

University of Chicago Medicine, Department of Medicine, Chicago, United States